Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37results about How to "Prevent and treat osteoporosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
ESTROGENIC EXTRACTS OF Pueraria lobata Willd. Ohwi of the Leguminosae Family AND USES THEREOF
Extracts of various species of the Leguminosae family have estrogenic properties. For example, aqueous and ethanolic extracts of Pueraria lobata Willd. Ohwi of the Leguminosae family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.
Owner:BIONOVO
Benzopyran compounds, compositions and uses thereof
InactiveUS9018244B2Prevent and treat osteoporosisUseful in therapyBiocideSkeletal disorderBenzopyranAnti estrogenic
Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.
Owner:OLEMA PHARMA
Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
InactiveUS20090258942A1Reduce riskReduced likelihoodBiocideNervous disorderDiseaseEstrogenic Effects
Estrogenic compositions comprising calycosin and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
Owner:BIONOVO
Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases
InactiveUS20090312274A1Abolished repressionReduce activationBiocideNervous disorderDiseaseEstrogenic Effects
Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
Owner:BIONOVO
ESTROGENIC EXTRACTS OF Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family AND USES THEREOF
ActiveUS20090068293A1Reduce riskReduced likelihoodBiocideSkeletal disorderEstrogenic EffectsLiliaceae
Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
Owner:BIONOVO
Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
InactiveUS20060004088A1Effect suppression of bone proliferationMilder side effectBiocideOrganic chemistryFuranSide effect
The present invention relates to furan derivatives and pharmaceutical compositions containing them to prevent and cure osteoporosis. The furan derivatives of the present invention have effect on bone proliferation with the side effect reduced, so that they can be used for bone disease.
Owner:OCT +1
Pharmaceutical composition containing bakuchiol for treating woman osteoporosis
InactiveUS7714026B2Increased riskPrevent and treat osteoporosisBiocideHydroxy compound active ingredientsOral medicationOsteopetrosis
The present invention discloses a novel use of bakuchiol or an extract containing bakuchiol in preventing or treating a woman suffering osteoporosis. An embodiment of this novel use is a pharmaceutical composition containing bakuchiol or an extract containing bakuchiol, which can be in the dosage forms of topical use, oral administration, injection or sustained release. The present invention also discloses a novel use of bakuchiol or an extract containing bakuchiol in preventing or treating a woman suffering breast cancer.
Owner:SINPHAR PHARM CO LTD
Pharmaceutical composition for preventing or treating osteoporosis or obesity comprising phenyltetrazole derivative
InactiveUS20100305324A1Prevent and treat osteoporosisPrevent obesityBiocideOrganic chemistrySecondary hyperlipidemiaObesity
A phamaceutical composition comprising a phenyltetrazole derivative of formula (I) or a pharmaceutical acceptable salt thereof is effective in preventing or treating osteoporosis, obesity, diabetes, or hyperlipidemia, by regulating protein TAZ.wherein, A is ethyl or n-butyl; R1 is methyl, —CH2OH, —CO2CH3, —CH2F, —CH(OCH3)2, —CH2OC(═O)CH3, styryl or —CH2OCH2SCH3; R2 is H, Br, —CO2CH3, phenyl, pyridin-2-yl, pyridin-3-yl, or styryl; R3 is H or methyl; X is CH or N; and P is H or —CH(CH3)OCH2CH3.
Owner:KOREA RES INST OF CHEM TECH
Pharmaceutical composition containing bakuchiol for treating woman osteoporosis
InactiveUS20050256209A1Increased riskPrevent and treat osteoporosisBiocideHydroxy compound active ingredientsOral medicationMedicine
The present invention discloses a novel use of bakuchiol or an extract containing bakuchiol in preventing or treating a woman suffering osteoporosis. An embodiment of this novel use is a pharmaceutical composition containing bakuchiol or an extract containing bakuchiol, which can be in the dosage forms of topical use, oral administration, injection or sustained release. The present invention also discloses a novel use of bakuchiol or an extract containing bakuchiol in preventing or treating a woman suffering breast cancer.
Owner:SINPHAR PHARM CO LTD
Novel cyclic hydrocarbon compounds for the treatment of diseases
InactiveUS20100317582A1Promote osteogenesisPrevent and treat osteoporosisBiocideNervous disorderDiseaseMedicinal chemistry
The invention relates to novel cyclic hydrocarbon compounds and derivatives thereof, processes for the preparation thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.
Owner:LEO PHARMA AS
ESTROGENIC EXTRACTS OF Anemarrhena asphodeloides Bge. from the Liliaceae Family and USES THEREOF
InactiveUS20090297638A1Reduce riskReduced likelihoodBiocideNervous disorderEstrogenic EffectsLiliaceae
Estrogenic extracts of Anemarrhena asphodeloides Bge. from the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
Owner:BIONOVO
Novel benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same
InactiveUS20090054642A1Good effectPrevent and treat osteoporosisOrganic active ingredientsBiocideBenzamidineTrabecular bone
The present invention relates to a novel benzamidine derivative, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzamidine derivative of the present invention effectively inhibits osteoclast differentiation at an extremely low concentration, and greatly increases the trabecular bone volume, and thus it can be advantageously used for the prevention and treatment of osteoporosis.
Owner:DONG WHA PHARM CO LTD
Pharmaceutical composition for treating primary osteoporosis
ActiveCN103405755APrevent and treat osteoporosisImprove low back painAmphibian material medical ingredientsPeptide/protein ingredientsAchyranthes bidentataOsteoporosis
The invention discloses a deodorized oviductus ranae egg oil composition for treating primary osteoporosis. The composition is characterized by comprising deodorized oviductus ranae egg oil, bovine bone collagen, bovine bone calcium, and achyranthes bidentata saponins. The composition is prepared into oral preparations, such as hard capsules, soft capsules, troches, granules, powder, pills, tea bags and medicinal liquors by using the synergistic effects of the ingredients. The composition can be applied to Chinese patent medicines or health foods, and has the effect of preventing osteoporosis.
Owner:长春仁人药业有限公司
Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs
ActiveUS10292971B2Reduce riskAvoid problemsOrganic active ingredientsOrganic chemistryDiseaseAnti estrogenic
![Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs](https://images-eureka.patsnap.com/patent_img/bcb54f52-e7f5-4fa6-8a85-2df60ce4d1db/US10292971-D00001.png "Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs")
![Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs](https://images-eureka.patsnap.com/patent_img/bcb54f52-e7f5-4fa6-8a85-2df60ce4d1db/US10292971-D00002.png "Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs")
![Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs](https://images-eureka.patsnap.com/patent_img/bcb54f52-e7f5-4fa6-8a85-2df60ce4d1db/US10292971-D00003.png "Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs")
Owner:OLEMA PHARMA
Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
The present invention relates to furan derivatives and pharmaceutical compositions containing them to prevent and cure osteoporosis. The furan derivatives of the present invention have effect on bone proliferation with the side effect reduced, so that they can be used for bone disease.
Owner:OCT +2
Benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same
InactiveUS7943646B2Good effectPrevent and treat osteoporosisBiocideOrganic active ingredientsBenzamidineTrabecular bone
The present invention relates to a novel benzamidine derivative, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzamidine derivative of the present invention effectively inhibits osteoclast differentiation at an extremely low concentration, and greatly increases the trabecular bone volume, and thus it can be advantageously used for the prevention and treatment of osteoporosis.
Owner:DONG WHA PHARM CO LTD
C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
InactiveUS20130324595A1Avoid spreadingEffective absorptionBiocideOrganic active ingredientsMetaboliteCellular mechanism
The present invention concerns a C-glucosidic ellagitannin compound or a metabolite thereof for use for altering the supramolecular arrangement of actin in an individual suffering from osteoporosis, cancer, bacterial infection, or viral infection. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and / or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, optionally detectably labeled, for in vitro use as a tool for studying cellular mechanisms involving actin, or for detecting F-actin in a cell.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
ActiveUS20180289679A1Enhanced inhibitory effectMinimal effectOrganic active ingredientsOrganic chemistryDiseaseAnti estrogenic
The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and / or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
![TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS](https://images-eureka.patsnap.com/patent_img/af0a2a87-3705-4355-8759-9e5f41a1cd62/US20180289679A1-D00001.png "TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS")
![TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS](https://images-eureka.patsnap.com/patent_img/af0a2a87-3705-4355-8759-9e5f41a1cd62/US20180289679A1-D00002.png "TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS")
![TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS](https://images-eureka.patsnap.com/patent_img/af0a2a87-3705-4355-8759-9e5f41a1cd62/US20180289679A1-D00003.png "TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS")
Owner:OLEMA PHARMA
Methods, compositions, and kits for predicting the effect of compounds on hot flash symptoms
InactiveUS20050064462A1Prevent and treat osteoporosisAvoid symptomsBiocideMicrobiological testing/measurementHot flashMedicine
The present invention provides methods, compositions, and kits, for determining the effects of one or more candidate compounds on hot flash symptoms. In certain aspects, the methods, compositions, and kits can be used to identify compounds that decrease the incidence of hot flash symptoms. In other aspects, the methods, compositions, and kits can be used to determine whether candidate compounds increase the incidence of undesirable hot flash symptoms when administered to a subject.
Owner:SIGNAL PHARM INC
Traditional Chinese medicine composition used for treating postmenopausal osteoporosis
InactiveCN109700918APrevent and treat osteoporosisEasy to carrySkeletal disorderUnknown materialsOsteoporosisLigusticum
The present invention relates to a traditional Chinese medicine composition and aims to provide the traditional Chinese medicine composition used for treating postmenopausal osteoporosis. The traditional Chinese medicine composition has functions of tonifying the kidneys and replenishing essence and strengthening bones and generating marrow, can regulate the decline of marrow-generating functionscaused by kidney qi deficiency and qi and blood deficiency in menopausal women, and prevents and treats the osteoporosis. The traditional Chinese medicine composition for treating the postmenopausal osteoporosis is composed of the following pharmaceutically effective components in parts by weight to form granules: 0.75-3 parts of prepared rehmannia root, 0.41-0.84 part of semen cuscutae, 0.75-2.25parts of radix achyranthis bidentatae, 6-9 parts of tortoise-plastron glue, 6-9 parts of deer-horn glue, 0.6-1.2 parts of Chinese yams, 0.3-1.5 parts of fructus corni, 1.81-4.55 parts of Chinese wolfberry fruits, 0.3-0.75 part of herba epimedii and 0.3-1.5 parts of glossy privet fruits.
Owner:SHANGHAI YANGPU CENT HOSPITAL
Nyasol and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
InactiveUS20120277169A1Reduce riskReduced likelihoodBiocideNervous disorderDiseaseEstrogenic Effects
Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
Owner:BIONOVO
Estrogenic Extracts of Anemarrhena Asphodeloides Bge. from the Liliaceae Family and Uses Thereof
InactiveUS20090297637A1Reduce riskReduced likelihoodBiocideNervous disorderEstrogenic EffectsFemale humans
Estrogenic extracts of Anemarrhena asphodeloides Bge. from the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
Owner:BIONOVO
Composition capable of improving osteoporosis and increasing bone density and preparation method of composition
ActiveCN108783467AIncreased hydroxyproline concentrationReduce bone lossOrganic active ingredientsPeptide/protein ingredientsFiberHydroxyproline
The invention relates to a composition capable of improving osteoporosis and increasing bone density. The composition comprises the following components in parts by weight of 10-30 parts of oligopeptide powder, 10-60 parts of saccharide substances, 10-60 parts of dietary fibers, 5-30 parts of maltodextrin, 5-15 parts of a calcium compound, and 0.1-2 parts of complex vitamins. When the compositionis eaten, the arthralgia can be notably reduced, the joint function can be improved, the hydroxyproline concentration in blood can be increased, the running off of sclerotin of post-menopause women suffering from osteoporosis is reduced, the treatment effect on anti-osteoporotic can be strengthened and prolonged, and the composition as a nutrient has the potential effect of preventing and treatingdegenerative arthritis and osteoporosis.
Owner:SINO PEPTIDE BEIJING HEALTH TECH CO LTD +1
ESTROGENIC EXTRACTS OF Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family AND USES THEREOF
ActiveUS20100173026A1Reduce riskReduced likelihoodBiocideSkeletal disorderEstrogenic EffectsFemale humans
Estrogenic extracts of Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.
Owner:BIONOVO
Methods and compositions for preventing and treating osteoporosis
ActiveUS10278995B1Prevent and treat osteoporosisReduce riskPowder deliveryAlgae medical ingredientsDocosahexaenoic acidOsteopoikilosis
Methods and compositions for treating and preventing osteoporosis are disclosed. Osteoporosis is prevented and treated by administering an effective amount of a composition to a patient. The composition may be prepared from New Zealand green-lipped mussel (Perna canaliculus) and may comprise one or more proteins, amino acids, minerals, sterol esters, sterols, polar lipids, triglycerides, fats, lipids, fatty acids, and polyunsaturated fatty acids (PUFAs) derived from the mussel. The active ingredients in the composition include one or more of an octadecatetraenoic acid (SDA), an eicosatetraenoic acid (ETA), an eicosapentaenoic acid (EPA), and a docosahexaenoic acid (DHA).
Owner:SVK LAB INC
Combined calcium, magnesium and vitamin D supplements
ActiveUS8324191B2Prevent and treat osteoporosisHigh densityBiocideOrganic active ingredientsAlpha-Lipoic AcidFracture risk
The present invention relates to oral nutritional and therapeutic products which are useful for providing vitamins and minerals required for bone health. The present invention is an oral nutritional and therapeutic composition of calcium succinate, magnesium R-(+)-alpha-lipoate, and Vitamin D for use in the maintenance of bone health, the optimization of bone growth, reducing the risk of bone fracture, and the prevention and treatment of osteoporosis. The pharmaceutical products and methods of the present invention are particularly useful in building bone mass, quality, and density during growth, maintaining bone mass, quality, and density over time, reducing bone fracture risk, and treating osteoporosis in men and women.
Owner:BIOLINK LIFE SCI
ESTROGENIC EXTRACTS OF Rheum palmatum L of the Polygonaceae family AND USES THEREOF
ActiveUS20090068294A1Decreased libidoPrevent and treat osteoporosisBiocideSkeletal disorderEstrogenic EffectsOsteopetrosis
Extracts of various species of the Polygonaceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Rheum palmatum L of the Polygonaceae family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.
Owner:BIONOVO
Estrogenic extracts of Rheum palmatum L of the polygonaceae family and uses thereof
ActiveUS9132161B2Decreased libidoPrevent and treat osteoporosisBiocideSkeletal disorderGynecologyEstrogenic Effects
Owner:BIONOVO
Compositon for preventing or treating osteoporosis
InactiveUS20210000900A1Improve bone formationInhibiting bone resorptionSkeletal disorderPlant ingredientsNatural productTraditional medicine
The present invention relates to a composition for preventing or treating osteoporosis, comprising a Gentiana scabra extract and a Sambucus williamsii extract, and it is an object of the present invention to provide the composition for preventing or treating osteoporosis, which is capable of increasing bone formation and inhibiting bone resorption. In addition, it is another object of the present invention to provide the composition for preventing or treating osteoporosis, which increases bioaffinity and has no side effects by comprising a Gentiana scabra extract and a Sambucus williamsii extract, which are natural products, thereby stably exhibiting an effect of preventing or treating osteoporosis.
Owner:PENS CO LTD +1
Chestnut and sesame edible sauced milk
InactiveCN104664462APrevent and treat osteoporosisDelay human agingFood preparationSyzygiumLigusticum chuanxiong
The invention discloses chestnut and sesame edible sauced milk. The chestnut and sesame edible sauced milk is prepared from main components and auxiliary components, wherein the main components are as follow: chestnut and sesame; and the auxiliary components are as follows: zanthoxylum schinifollum, syzygium aromaticum, honey, monosodium glutamate, table salt, soy sauce, ground pepper, cumin powder, ligusticum wallichii powder and myrcia. The chestnut and sesame edible sauced milk enriches the need of food market, remedies the blank of the sauce type milk products, is convenient to carry, is suitable for various people to eat, is available in raw material, is low in cost, and does not need fermentation treatment in the processing course, and the method is simple and feasible.
Owner:张书秘
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com